title: [Feasibility study of adjuvant chemotherapy with S-1 for pancreatic adenocarcinoma].
abstract: BACKGROUND
  The aim of this study was to assess the feasibility of using S-1 as adjuvant chemotherapy after the resection of pancreatic cancer.
  
  
  METHODS
  S-1 was initially administered or ally at a dose of 50 mg twice daily for 14 days, followed by a rest period of seven days to complete one course. Administration was repeated with dose escalation in each cycle until the recommended dose (RD; 80 mg/m2, maximum 120 mg/day), unless grade 3 adverse events were observed. Administration was planned to continue at least 6 months (eight courses).
  
  
  RESULTS
  Eighteen patients who had undergone resection of pancreatic adenocarcinoma were enrolled in this study. The RD could be administered to 12 patients(67%), and 80% of the RD was given to five patients(28%). Although grade 3 anemia occurred in one patient, grade 4 hematologic adverse events were not observed. Grade 3 cutaneous toxicity (hand-foot syndrome)was observed in two patients. The cumulative relative total administered dose rate of S-1 was 0. 86. The 3-year relapse-free survival rate was 31. 4%, and the median overall survival time was 25. 3 months.
  
  
  CONCLUSIONS
  Long-term postoperative administration of S-1 at the RD is safe and appears to be a promising method of adjuvant chemotherapy.
authors.affiliation: Department of Surgery, Toranomon Hospital.
authors.forename: Masamichi
authors.initials: M
authors.lastname: Matsuda
authors.forename: Goro
authors.initials: G
authors.lastname: Watanabe
authors.forename: Masaji
authors.initials: M
authors.lastname: Hashimoto
authors.forename: Kazunari
authors.initials: K
authors.lastname: Sasaki
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000601:surgery; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D004338:Drug Combinations; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010094:Oxonic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000601:surgery; D010198:Pancytopenia / Q000139:chemically induced; D015996:Survival Rate; D005641:Tegafur / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid